Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 19/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3555315 | 0.85 | HSD11B1 (0.52) | HSD11B1NR1I2CYP2C19HSD11B2 | |
| SCHEMBL5635264 | 0.79 | HSD11B1 (0.68) | HSD11B1NR1I2HSD11B2 | |
| SCHEMBL1108706 | 0.78 | HSD11B1 (0.44) | HSD11B1NR1I2CYP2C19HSD11B2 | |
| Hydrochloric Acid SCHEMBL1100547 | 0.78 | HSD11B1 (0.43) | HSD11B1NR1I2CYP2C19HSD11B2 | |
| SCHEMBL2667471 | 0.76 | HSD11B1 (0.79) | HSD11B1NR1I2CYP2C19HSD11B2 | |
| SCHEMBL1108790 | 0.74 | HSD11B1 (0.46) | HSD11B1NR1I2HSD11B2 | |
| SCHEMBL4354287 | 0.73 | HSD11B1 (0.78) | HSD11B1NR1I2HSD11B2 | |
| SCHEMBL4538415 | 0.72 | HSD11B1 (0.75) | HSD11B1NR1I2CYP2C19HSD11B2 | |
| SCHEMBL1108714 | 0.72 | MEN1 (0.45) | HSD11B1NR1I2HSD11B2 | |
| SCHEMBL1108713 | 0.71 | HSD11B1 (0.45) | HSD11B1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838544-B2 | Heterocyclic inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and methods of using the same | INCYTE CORPORATION (US) | 2010-11-23 | — | — | US | claimed |
| EP-2018378-A2 | HETEROCYCLIC INHIBITORS OF 11-B HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME | Incyte Corporation (US) | 2009-01-28 | — | — | EP | claimed |
| WO-2007137066-A2 | HETEROCYCLIC INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2007-11-29 | — | — | WO | claimed |
| US-20070270424-A1 | Heterocyclic inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 and methods of using the same | INCYTE CORPORATION | 2007-11-22 | — | — | US | claimed |
| US-7838544-B2 | Heterocyclic inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and methods of using the same | INCYTE CORPORATION (US) | 2010-11-23 | — | — | US | disclosed |
| US-7838544-B2 | Heterocyclic inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and methods of using the same | INCYTE CORPORATION (US) | 2010-11-23 | — | — | US | disclosed |
| US-7838544-B2 | Heterocyclic inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and methods of using the same | INCYTE CORPORATION (US) | 2010-11-23 | — | — | US | disclosed |
| EP-2018378-A2 | HETEROCYCLIC INHIBITORS OF 11-B HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME | Incyte Corporation (US) | 2009-01-28 | — | — | EP | disclosed |
| WO-2007137066-A2 | HETEROCYCLIC INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007137066-A2 | HETEROCYCLIC INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270424-A1 | Heterocyclic inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 and methods of using the same | INCYTE CORPORATION | 2007-11-22 | — | — | US | disclosed |
| US-20070270424-A1 | Heterocyclic inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 and methods of using the same | INCYTE CORPORATION | 2007-11-22 | — | — | US | disclosed |
| US-20070270424-A1 | Heterocyclic inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 and methods of using the same | INCYTE CORPORATION | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270424-A1 | Heterocyclic inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 and methods of using the same | HSD11B1, HSD17B1, HSD17B11 | HSD11B1 1/4885NR1I2 197/4885CYP2C19 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.